One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
What Does Improvement Mean?: Interpreting Progress and Evidence in Hypertrophic Cardiomyopathy
Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis
The Emerging Role of ECG-AI as a Digital Risk Biomarker for Incident Heart Failure
Heart Failure Quality of Care Among Asian Patients in the United States
Asian American Heart Failure Care: Why Disaggregated Subgroup Data Matters
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial
Aficamten and the Future of Obstructive Hypertrophic Cardiomyopathy Management
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy
Aficamten vs Metoprolol: A Turning Point in Obstructive Hypertrophic Cardiomyopathy Care?: The MAPLE-HCM Results
Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial
Drug Therapy in Nonobstructive Hypertrophic Cardiomyopathy: Out of the Darkness Into the Light
Cardiomyopathies: Nationwide Trends in Prevalence, Incidence, and Mortality (2004–2023)
